New Zealand markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9700-0.1000 (-4.83%)
At close: 04:00PM EST
1.9501 -0.02 (-1.01%)
After hours: 07:55PM EST

Context Therapeutics Inc.

3675 Market Street
Suite 200
Philadelphia, PA 19104
United States
267 225 7416
https://www.contexttherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1

Key executives

NameTitlePayExercisedYear born
Mr. Martin A. LehrCo-Founder, CEO & Director250kN/A1984
Dr. Tarek Sahmoud M.D., Ph.D.Chief Medical Officer26.61kN/A1962
Dr. William F. Rencher Ph.D.Head of CMC & Regulatory246.47kN/A1959
Dr. Felix Kim Ph.D.Co-founder & Chair of Scientific Advisory BoardN/AN/AN/A
Ms. Jennifer Minai-AzaryChief Financial OfficerN/AN/A1977
Mr. Alex C. Levit Esq.Chief Legal Officer & Corp. Sec.N/AN/A1979
Dr. Evan G. DickSr. VP of R&DN/AN/A1952
Ms. Eileen Kittrick CPAControllerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. Context Therapeutics Inc. was founded in 2015 and is based in Philadelphia, Pennsylvania.

Corporate governance

Context Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.